Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01088256
Other study ID # Etoricox09-10
Secondary ID 2009-015496-27
Status Terminated
Phase Phase 2
First received March 16, 2010
Last updated August 23, 2012
Start date February 2011
Est. completion date August 2012

Study information

Verified date August 2012
Source Ruhr University of Bochum
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine the efficacy of etoricoxib on pain patients. The investigators assume that patients with neuropathic pain will have greater pain relief then patients on placebo.


Description:

Animal experiments analysing anti-hyperalgesic effects of Coxibs show inconsistent results due to different used dosages and varying different pain models. Theoretical the use of NSAIDs is rational, particularly of Coxibs as a part of the neuropathic pain management. But in the newest topical review, there is no valid information available about the effectiveness of these drugs in human neuropathic pain models or in patients with different underlying mechanism, e.g. with or without hyperalgesia.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients over 18 years with

- Persistent moderate or severe pain (> 4 on NRS (1..10)) at rest (average of three daily assessments using a diary for at least two days) .

- Neuropathic pain associated with a clinical and neurologically proven peripheral nerve injury, radiculopathy, postherpetic neuralgia or polyneuropathy or CRPS

- One of the two following QST phenotypes at the baseline assessment:

- signs of peripheral hyperalgesia (that means, pathological decreased heat pain threshold and/or pathological decreased muscle pain threshold)

- without signs of peripheral hyperalgesia (no pathological decreased heat - and/or muscle pain threshold)

- Patients of both gender

- Signed consent form

- Patients with the ability to understand and follow the instructions of the doctor

Exclusion Criteria:

- Excluded will be patients Parkinson's disease or a history of cerebral vascular insult or nerve injury.

Excluded will be also all patients with contradictions for the use of Etoricoxib:

- Hypersensitivity to the active substance or to any of the excipients.

- Active peptic ulceration or active gastrointestinal (GI) bleeding.

- Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetyl-salicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.

- Pregnancy and lactation

- Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score =10).

- Estimated renal creatinine clearance <30 ml/min.

- Inflammatory bowel disease.

- Congestive heart failure (NYHA II-IV).

- Patients with hypertension whose blood pressure is persistently elevated above 140/90mmHg and has not been adequately controlled

- Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.

- Intake of one of the following drugs (current or in the last 3 days)

- selective-serotonin-reuptake-inhibitor

- cetoconazole

- rifampicin

- phenytoin

- carbamazepine

- dexamethasone or other systemic corticoids

- traditional nonsteroidal antiphlogistics

- cyclooxygenase-inhibitors

- immunosuppressives

- TNF-a-inhibitors

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Intervention

Drug:
Etoricoxib
the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
placebo
patients get one pill of placebo (sugar-pill) per day for 8 days.

Locations

Country Name City State
Germany Bergmannsheil department of pain therapy Bochum Nordrhein-Westfalen

Sponsors (1)

Lead Sponsor Collaborator
Ruhr University of Bochum

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Superior improvement of peripheral hyperalgesia at day six after initiation of Cox-2-inhibiting-medication in comparison to placebo 12 month No
Secondary Reduction of the average on-going pain reduction of the average on-going pain decrease of the neuropathic symptoms intensity (NPSI score) decrease of the patients global impression of change (PGIC) decrease of the frequency and cumulative 7 day dosage of rescue medication 12 month No
See also
  Status Clinical Trial Phase
Completed NCT04546334 - Erector Spinae Plane Block in Post-herpetic Neuralgia N/A
Completed NCT01688947 - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) Phase 2
Terminated NCT01744522 - Leech Therapy for Postherpetic Neuralgia N/A
Completed NCT00566904 - New Topical Treatment for Continued Pain After Shingles Phase 1
Completed NCT00478179 - Study of a Bupivacaine Patch (Eladurâ„¢) to Treat Post- Herpetic Neuralgia Phase 2
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Terminated NCT01603394 - Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Phase 4
Completed NCT01228838 - Study of NGX-1998 for the Treatment of Postherpetic Neuralgia Phase 2
Completed NCT01251211 - Botulinum Toxin in Peripheral Neuropathic Pain Phase 4
Completed NCT00612105 - Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) Phase 2
Recruiting NCT04560361 - The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia N/A
Recruiting NCT05568186 - Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
Recruiting NCT04664530 - The Study on the Esketamine in the Treatment of Postherpetic Neuralgia Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Completed NCT00885586 - Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Phase 4
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00981227 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Phase 2
Completed NCT00238511 - An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00007501 - Shingles Prevention Study Phase 3
Completed NCT04594226 - Electroacupuncture Therapy for Treating Postherpetic Neuralgia N/A